Researchers at The Rockefeller University have reported that when cells run short of the amino acid arginine, they stop making enough of the surface molecules that allow the immune system to recognize infected and cancerous cells. In mice, correcting the shortage through diet reduced colon tumors and improved outcomes from influenza and SARS-CoV-2 infection.
The work was published in the journal Cell on July 30, and the animal results are the findings. This is laboratory and mouse research. It has not been tested in people, and the senior author said so directly.
"I don't want the takeaway to be that everyone should be just consuming arginine all the time," Sohail Tavazoie, who heads Rockefeller's Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology, told Science News. He said it is far too early to know whether arginine supplements would prevent or treat these diseases in humans.
The Mechanism the Team Proposed
Every cell displays fragments of the proteins it is making on surface molecules called MHC class I. Killer T cells patrol tissue, reading those displays. When a cell is infected or has become cancerous, the abnormal fragments on its MHC class I molecules are what mark it for destruction.
First author Qiushuang Wu, a postdoctoral researcher in the Tavazoie lab, began by looking at what happens to gene expression when arginine runs low. Across models of colon cancer, influenza and SARS-CoV-2, arginine turned out to be the most depleted amino acid. In cell culture, she identified 414 proteins that dropped to abnormally low levels when arginine was restricted, including the products of a trio of HLA genes that encode MHC class I.
The proposed mechanism is specific, and it is a supply problem rather than a signaling one. According to the Rockefeller announcement of the findings and the study abstract in Cell, MHC class I proteins contain long stretches encoded by arginine codons. In an arginine-starved environment, ribosomes stall while trying to translate them, so fewer of the molecules are made, and fewer antigens reach the cell surface. Cells become harder for T cells to see and kill.
The finding is not that arginine boosts immunity in general. It is that nutrient availability tunes one specific step, antigen presentation, that determines whether the immune system can identify its target at all.
Results in the Animals
Mice fed an arginine-restricted diet had lower MHC class I levels and developed more colon tumors. Mice given higher dietary arginine, an amount Science News reported as the equivalent of roughly 10 grams a day in humans, showed the reverse pattern.
The team then repeated the dietary experiments in mouse models of influenza and SARS-CoV-2 infection, working with H. Heinrich Hoffmann of Charles Rice's Laboratory of Virology and Infectious Disease at Rockefeller. Animals on arginine-rich diets had milder illness, with less virus and less inflammation in the lungs. In the influenza experiments, giving arginine after infection had already begun also improved survival, which Wu described as surprising.
One experiment matters more than the others for interpreting the whole paper. As reported in the full study in Cell, the disease-modifying effects disappeared in mice lacking beta-2 microglobulin, which cannot make functional MHC class I. That control separates the effect from a generic metabolic change and supports the antigen-presentation explanation.
MedicalDaily Evidence Check
This is mechanistic laboratory work in cell cultures and mouse models, published in a peer-reviewed journal after a review process that ran from submission in September 2025 to acceptance in July 2026. There were no human participants, no clinical endpoints, and no human dosing data. The research was supported in part by the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller and the Weill Cancer East Hub.
The study shows that arginine availability controls MHC class I translation and that manipulating dietary arginine changed tumor burden and infection outcomes in mice. It does not show that arginine supplements prevent or treat cancer or viral illness in people. Mouse immunology and dietary metabolism differ substantially from human physiology, and many promising mouse findings do not replicate.
Current medical guidance has not changed. No professional body recommends arginine supplementation for cancer prevention or infection resistance, and this paper does not create a basis for one.
The Reason Caution Is Not Optional Here
Arginine is not an inert nutrient. It is a precursor to nitric oxide, and supplemental arginine can lower blood pressure, which matters for anyone taking antihypertensives or nitrates. It has been associated with worse outcomes in some critically ill patient populations. People with herpes simplex infections are sometimes advised to limit arginine intake because the virus uses it for replication. People with kidney or liver impairment process amino acid loads differently.
One oncology consideration runs in the opposite direction. Several investigational cancer therapies work by depleting arginine, on the theory that certain tumors cannot synthesize it themselves. Both approaches cannot be right for every tumor type, a signal that the biology is context-dependent.
Anyone taking a supplement should tell their clinician, and anyone in active cancer treatment should not add one without asking their oncology team first.
Next Steps in This Line of Research
Tavazoie said he is interested in following up with clinical studies of arginine supplementation in people, and the lab is also investigating whether dietary changes in other amino acids produce effects in different disease contexts.
Any human work would need to start small. Dose-finding studies would come first, then measurement of whether supplementation actually raises MHC class I expression in human tissue, before a trial with clinical endpoints could be designed. Each step is a point where the effect could fail to translate.
Arginine is already abundant in protein-rich foods, including nuts, seeds, poultry, fish, legumes and dairy. For someone eating adequate protein, this paper describes a deficiency state rather than a supplementation opportunity. The populations where arginine depletion is documented are people with advanced cancer, serious infection and critical illness, which is exactly where intervention is least safe to attempt unsupervised.
The honest summary is that this is a well-controlled piece of basic science that identifies a plausible and testable mechanism. It is a reason for researchers to run human studies. It is not a reason to buy a supplement.
Frequently Asked Questions
What did the study find? That arginine shortage stalls translation of MHC class I, the molecules cells use to display abnormal proteins to killer T cells. In mice, restricting arginine increased colon tumors and worsened viral infection, while increasing it did the reverse.
Was this study done in people? No. The work used cell cultures and mouse models. There were no human participants and no clinical outcomes.
Should I start taking arginine supplements? No professional guideline recommends it for these purposes, and the senior author cautioned directly against that conclusion. Talk with a clinician before adding any supplement, particularly if you take blood pressure medication or are in cancer treatment.
Where was the research published? In the journal Cell, published online July 30, 2026, by researchers at The Rockefeller University.
What is MHC class I? A set of molecules on nearly every cell that display protein fragments to the immune system. They are how T cells distinguish a healthy cell from an infected or cancerous one.
Are there risks to arginine supplementation? Possibly, depending on the person. Arginine can lower blood pressure, may affect herpes simplex activity, and is handled differently by people with kidney or liver disease. Some cancer therapies deliberately deplete arginine.
What happens next? The lab has said it wants to pursue clinical studies in people. Any human research would begin with small dose-finding and biomarker studies before clinical endpoints could be tested.
Researchers at The Rockefeller University have reported that when cells run short of the amino acid arginine, they stop making enough of the surface molecules that allow the immune system to recognize infected and cancerous cells. In mice, correcting the shortage through diet reduced colon tumors and improved outcomes from influenza and SARS-CoV-2 infection.
The work was published in the journal Cell on July 30, and the animal results are the finding. This is laboratory and mouse research. It has not been tested in people, and the senior author said so directly.
"I don't want the takeaway to be that everyone should be just consuming arginine all the time," Sohail Tavazoie, who heads Rockefeller's Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology, told Science News. He said it is far too early to know whether arginine supplements would prevent or treat these diseases in humans.
The Mechanism the Team Proposed
Every cell displays fragments of the proteins it is making on surface molecules called MHC class I. Killer T cells patrol tissue reading those displays. When a cell is infected or has become cancerous, the abnormal fragments on its MHC class I molecules are what mark it for destruction.
First author Qiushuang Wu, a postdoctoral researcher in the Tavazoie lab, began by looking at what happens to gene expression when arginine runs low. Across models of colon cancer, influenza and SARS-CoV-2, arginine turned out to be the most depleted amino acid. In cell culture, she identified 414 proteins that dropped to abnormally low levels when arginine was restricted, including the products of a trio of HLA genes that encode MHC class I.
The proposed mechanism is specific, and it is a supply problem rather than a signaling one. According to the Rockefeller announcement of the findings and the study abstract in Cell, MHC class I proteins contain long stretches encoded by arginine codons. In an arginine-starved environment, ribosomes stall while trying to translate them, so fewer of the molecules are made and fewer antigens reach the cell surface. Cells become harder for T cells to see and kill.
The finding is not that arginine boosts immunity in general. It is that nutrient availability tunes one specific step, antigen presentation, that determines whether the immune system can identify its target at all.
Results in the Animals
Mice fed an arginine-restricted diet had lower MHC class I levels and developed more colon tumors. Mice given higher dietary arginine, an amount Science News reported as the equivalent of roughly 10 grams a day in humans, showed the reverse pattern.
The team then repeated the dietary experiments in mouse models of influenza and SARS-CoV-2 infection, working with H. Heinrich Hoffmann of Charles Rice's Laboratory of Virology and Infectious Disease at Rockefeller. Animals on arginine-rich diets had milder illness, with less virus and less inflammation in the lungs. In the influenza experiments, giving arginine after infection had already begun also improved survival, which Wu described as surprising.
One experiment matters more than the others for interpreting the whole paper. As reported in the full study in Cell, the disease-modifying effects disappeared in mice lacking beta-2 microglobulin, which cannot make functional MHC class I. That control separates the effect from a generic metabolic change and supports the antigen-presentation explanation.
MedicalDaily Evidence Check
This is mechanistic laboratory work in cell cultures and mouse models, published in a peer-reviewed journal after a review process that ran from submission in September 2025 to acceptance in July 2026. There were no human participants, no clinical endpoints and no human dosing data. The research was supported in part by the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller and the Weill Cancer East Hub.
The study shows that arginine availability controls MHC class I translation and that manipulating dietary arginine changed tumor burden and infection outcomes in mice. It does not show that arginine supplements prevent or treat cancer or viral illness in people. Mouse immunology and dietary metabolism differ substantially from human physiology, and many promising mouse findings do not replicate.
Current medical guidance has not changed. No professional body recommends arginine supplementation for cancer prevention or infection resistance, and this paper does not create a basis for one.
The Reason Caution Is Not Optional Here
Arginine is not an inert nutrient. It is a precursor to nitric oxide, and supplemental arginine can lower blood pressure, which matters for anyone taking antihypertensives or nitrates. It has been associated with worse outcomes in some critically ill patient populations. People with herpes simplex infections are sometimes advised to limit arginine intake because the virus uses it for replication. People with kidney or liver impairment process amino acid loads differently.
One oncology consideration runs in the opposite direction. Several investigational cancer therapies work by depleting arginine, on the theory that certain tumors cannot synthesize it themselves. Both approaches cannot be right for every tumor type, a signal that the biology is context-dependent.
Anyone taking a supplement should tell their clinician, and anyone in active cancer treatment should not add one without asking their oncology team first.
Next Steps in This Line of Research
Tavazoie said he is interested in following up with clinical studies of arginine supplementation in people, and the lab is also investigating whether dietary changes in other amino acids produce effects in different disease contexts.
Any human work would need to start small. Dose-finding studies would come first, then measurement of whether supplementation actually raises MHC class I expression in human tissue, before a trial with clinical endpoints could be designed. Each step is a point where the effect could fail to translate.
Arginine is already abundant in protein-rich foods, including nuts, seeds, poultry, fish, legumes and dairy. For someone eating adequate protein, this paper describes a deficiency state rather than a supplementation opportunity. The populations where arginine depletion is documented are people with advanced cancer, serious infection and critical illness, which is exactly where intervention is least safe to attempt unsupervised.
The honest summary is that this is a well-controlled piece of basic science that identifies a plausible and testable mechanism. It is a reason for researchers to run human studies. It is not a reason to buy a supplement.
Related MedicalDaily Coverage
FDA-Cleared AI Reads Your Routine ECG and Flags Hidden Heart Failure Before You Have Any Symptoms
Frequently Asked Questions
What did the study find? That arginine shortage stalls translation of MHC class I, the molecules cells use to display abnormal proteins to killer T cells. In mice, restricting arginine increased colon tumors and worsened viral infection, while increasing it did the reverse.
Was this study done in people? No. The work used cell cultures and mouse models. There were no human participants and no clinical outcomes.
Should I start taking arginine supplements? No professional guideline recommends it for these purposes, and the senior author cautioned directly against that conclusion. Talk with a clinician before adding any supplement, particularly if you take blood pressure medication or are in cancer treatment.
Where was the research published? In the journal Cell, published online July 30, 2026, by researchers at The Rockefeller University.
What is MHC class I? A set of molecules on nearly every cell that display protein fragments to the immune system. They are how T cells distinguish a healthy cell from an infected or cancerous one.
Are there risks to arginine supplementation? Possibly, depending on the person. Arginine can lower blood pressure, may affect herpes simplex activity, and is handled differently by people with kidney or liver disease. Some cancer therapies deliberately deplete arginine.
What happens next? The lab has said it wants to pursue clinical studies in people. Any human research would begin with small dose-finding and biomarker studies before clinical endpoints could be tested.
